Beta-amyloid (Aβ) peptides derived from amyloid precursor protein are found in human cerebrospinal fluid (CSF) and have proven to be informative biomarkers with respect to neurodegeneration, especially Alzheimer’s disease (AD). Quantification of A&beta peptides has proven useful in discriminating AD from other dementias and in staging AD patients with respect to the natural progression of the disease. The Aβ Peptide Panel 1 (4G8) provides a sensitive and efficient means to monitor changes in concentrations of the Aβ peptides and has been validated for measurement in human CSF and mouse plasma. These assays are also compatible with other sample types, including conditioned neuronal cell culture medium, cell lysates, and tissue homogenates such as mouse brain. They provide a platform for use in early discovery from pre-clinical through clinical studies. These assays were developed according to “fit for purpose” principles and are consistent with guidance from the Clinical and Laboratory Standards Institute. The Aβ Peptide Panel 1 (4G8) Kit provides assay-specific components for the quantitative determination of Aβ38, Aβ40, and Aβ42 in human and rodent samples. These validated assays use peptide-specific capture antibodies with an anti-beta amyloid (17-24) antibody (4G8 clone) as the detection antibody. The 6E10 clone is provided by Covance Research Products, Inc.